EXETER,
N.H., Nov. 28, 2023 /PRNewswire/
-- Vapotherm, Inc. (NYSE: VAPO), a global medical technology
company focused on the development and commercialization of its
proprietary Vapotherm high velocity therapy® products, which are
used to treat patients of all ages suffering from respiratory
distress is excited to announce the participation of over
8,000 clinicians in interactive, digital based, evidence based
education focused on a variety of respiratory clinical topics. The
education was free to clincians in celebration of Respiratory Care
Week, and continued through the month of October culminating in the
American Association for Respiratory Care Congress 5-8
November.
Dr. Jessica Whittle, Chief
Medical Officer at Vapotherm, shared her enthusiasm: "About 7,000
clinicians initially registered for our educational programs, and
we are thrilled that even more participated as the value became
more well-known. Vapotherm is committed to partnering with
clinicans to provide the highest level of patient care.
High-quality, readily accessible, clinical education is crucial to
that mission."
Joe Army, Chief Executive
Officer, emphasized his excitement: "The power of our educational
platform is tremendous: our devices are in over 2,400 hospitals in
the U.S., and we have over 50,000 clinicians in our Vapotherm
Academy. We take immense pride in leading the respiratory industry
in both innovation and education."
Dr. Whittle and Joe Army were
both present at the American Association for Respiratory Care
Congress to celebrate this accomplishment and educate about the HVT
2.0 system.
About Vapotherm
Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and
manufacturer of advanced respiratory technology based in
Exeter, New Hampshire, USA. The
Company develops innovative, comfortable, non-invasive technologies
for respiratory support of patients with chronic or acute breathing
disorders. Over 4.1 million patients have been treated with the use
of Vapotherm high velocity therapy® systems. For more information,
visit www.vapotherm.com.
Vapotherm high velocity therapy is mask-free non-invasive
respiratory support and is a front-line tool for relieving
respiratory distress—including hypercapnia, hypoxemia, and dyspnea.
It allows for the fast, safe treatment of undifferentiated
respiratory distress with one tool. The HVT 2.0 and Precision Flow
systems' mask-free interface delivers optimally conditioned
breathing gases, making it comfortable for patients and reducing
the risks and care complexities associated with mask therapies.
While being treated, patients can talk, eat, drink and take oral
medication.
Investor Contact:
John Landry, SVP and CFO
http://investors.vapotherm.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/vapotherm-educates-over-8-000-clinicians-in-respiratory-care-month-301999854.html
SOURCE Vapotherm, Inc.
